Strand-selective base editing of human mitochondrial DNA using mitoBEs

Nat Biotechnol. 2024 Mar;42(3):498-509. doi: 10.1038/s41587-023-01791-y. Epub 2023 May 22.

Abstract

A number of mitochondrial diseases in humans are caused by point mutations that could be corrected by base editors, but delivery of CRISPR guide RNAs into the mitochondria is difficult. In this study, we present mitochondrial DNA base editors (mitoBEs), which combine a transcription activator-like effector (TALE)-fused nickase and a deaminase for precise base editing in mitochondrial DNA. Combining mitochondria-localized, programmable TALE binding proteins with the nickase MutH or Nt.BspD6I(C) and either the single-stranded DNA-specific adenine deaminase TadA8e or the cytosine deaminase ABOBEC1 and UGI, we achieve A-to-G or C-to-T base editing with up to 77% efficiency and high specificity. We find that mitoBEs are DNA strand-selective mitochondrial base editors, with editing results more likely to be retained on the nonnicked DNA strand. Furthermore, we correct pathogenic mitochondrial DNA mutations in patient-derived cells by delivering mitoBEs encoded in circular RNAs. mitoBEs offer a precise, efficient DNA editing tool with broad applicability for therapy in mitochondrial genetic diseases.

MeSH terms

  • CRISPR-Cas Systems / genetics
  • Cytosine
  • DNA, Mitochondrial / genetics
  • Deoxyribonuclease I / genetics
  • Gene Editing* / methods
  • Humans
  • Mitochondria / genetics
  • Mitochondrial Diseases* / genetics
  • Mitochondrial Diseases* / therapy
  • RNA, Guide, CRISPR-Cas Systems

Substances

  • DNA, Mitochondrial
  • RNA, Guide, CRISPR-Cas Systems
  • Deoxyribonuclease I
  • Cytosine